The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000772347
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
20/04/2026
Date registered
Help: Date registered
29/06/2026
Date last updated
Help: Date last updated
29/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
29/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
How can genetic testing improve medication safety and effectiveness in Aboriginal and Torres Strait Islander people with chronic diseases?
Scientific title
Pharmacogenomic-guided medication management in Aboriginal and Torres Strait Islander adults with chronic disease: a multi-site interventional study evaluating adverse drug reactions/interactions and medication response
Additional trial identifiers [1] 317039 0
Nil
Universal Trial Number (UTN)
Trial acronym
PGx–First Nations Study
Related trial records

Health condition
Health condition(s) studied:
Adverse Drug Reactions 341538 0
Chronic kidney disease 342590 0
Cardiovascular Disease 342595 0
Hypertension 342596 0
Mental illness 342597 0
Acute pain 342598 0
Condition category
Condition code
Cardiovascular 337612 337612 0 0
Other cardiovascular diseases
Cardiovascular 338222 338222 0 0
Hypertension
Renal and Urogenital 338223 338223 0 0
Kidney disease
Mental Health 338224 338224 0 0
Depression
Mental Health 338225 338225 0 0
Psychosis and personality disorders
Inflammatory and Immune System 338226 338226 0 0
Other inflammatory or immune system disorders
Anaesthesiology 338736 338736 0 0
Pain management

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will undergo pharmacogenomic testing using a blood sample (~5 mL) to identify genetic variants that influence medication response. Participants will attend screening, consent, intervention, and follow-up appointments over approximately 24 weeks.
The intervention consists of:
Screening phase
During standard clinical appointments, clinicians or Clinical Coordinators identify potentially eligible patients who are prescribed an index medication and invite them to participate in the study. Interested participants are referred to an Aboriginal Health Worker (AHW) or Research Nurse, who contacts potential participants and arranges a study information appointment.
Appointment 1 (Screening)
The AHW/Research Nurse explains the study and provides the Participant Information and Consent Form (PICF). Participants who are not interested are not contacted further.
Appointment 2 (Recruitment/Consent – Week 1)
The AHW/Research Nurse conducts the consent interview and obtains informed consent. Participants who do not consent are withdrawn from further study procedures.
Appointment 3 (Intervention – Week 2–3)
Participants attend pathology collection for blood sample collection (~5 mL). Blood samples undergo pharmacogenomic sequencing using a targeted gene panel. Clinical Coordinators administer baseline electronic questionnaires and collect relevant clinical information from electronic health records. Where required, samples are sent to a National Association of Testing Authorities (NATA)-accredited laboratory for validation of clinically actionable findings.
The study includes participants prescribed selected medications associated with chronic disease management and known pharmacogenomic relevance. These include:
Mental illness
• Paroxetine
• Venlafaxine
• Risperidone
• Sertraline
Cardiovascular disease (CVD), Chronic Kidney Disease (CKD), and Hypertension
• Atorvastatin
• Simvastatin
Acute pain management
• Celecoxib
Appointment 4 (Following sequencing and validation – approximately Week 3 onwards)
Where clinically actionable pharmacogenomic findings are identified, a report summarising the results and clinical recommendations will be provided to the treating clinician. Medication adjustments may be made based on these results. Pharmacogenomic results and established clinical guidelines will be used by clinicians to guide both initial prescribing decisions and any subsequent prescriptions during the follow-up period.
Pharmacogenomic results are returned to treating clinician and participants are informed of any medication dose or selection changes guided by pharmacogenomic findings. Treating clinicians may adjust medications using pharmacogenomic results alongside internationally recognised guidelines including the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines, where clinically applicable.
Participants are informed during the consent process that only clinically actionable pharmacogenomic results will be returned. If no clinically actionable variants are identified, or findings do not meet criteria for return, participants will not receive an individual pharmacogenomic report and will continue receiving standard clinical care. No medication changes will be made where no actionable findings are identified.
The intervention is delivered within hospital and community healthcare settings, including Toowoomba Hospital, Logan Hospital, and Carbal Medical Services. Clinical Coordinators, Research Nurses, and clinicians are responsible for study procedures, while Aboriginal Health Workers provide culturally appropriate support to participants throughout recruitment, consent, and follow-up.
Follow-up (Week 12)
Clinical Coordinators follow up participants and conduct Week 12 surveys. Additional appointments with treating clinicians may be arranged if required.
Final Follow-up (Week 24)
Clinical Coordinators conduct final Week 24 follow-up surveys. Additional clinician appointments may be arranged if required.
Intervention adherence and fidelity will be monitored through participant follow-up surveys, review of medication changes, and relevant medical record review.
Participants who undergo medication adjustments will be followed for a six-month period to monitor the frequency and severity of adverse drug reactions. Adverse events will be assessed using a standardised clinical grading scale, focusing on events rated as moderate to severe.
Participants may withdraw from the study at any time.
Intervention code [1] 333798 0
Treatment: Other
Intervention code [2] 333799 0
Diagnosis / Prognosis
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345115 0
Composite outcome of frequency and severity of clinically relevant drug-genotype associated adverse drug reactions (ADRs)
Timepoint [1] 345115 0
Baseline, (Week 12)3 months, and ( Week 24)6 months after intervention commencement (primary timepoint: 6 months( week 24)
Secondary outcome [1] 460533 0
Proportion of participants with pharmacogenomic-guided medication changes
Timepoint [1] 460533 0
Assessed following return of pharmacogenomic results (approximately Week 3 onwards), with follow-up assessments at Week 12 and Week 24.
Secondary outcome [2] 460534 0
Identification of clinically actionable gene–drug interactions
Timepoint [2] 460534 0
Assessed following pharmacogenomic testing and validation of actionable findings (approximately Week 2–4 after blood collection).

Eligibility
Key inclusion criteria
Aboriginal and/or Torres Strait Islander adults aged 18 years or older
Participants must be either initiating their first prescription for study-relevant medications in routine clinical care, or currently receiving treatment with these medications, with or without reported side effects
Receiving care at participating study sites (e.g. hospital or community healthcare settings)
Able and willing to provide informed consent
Willing to provide a blood sample for pharmacogenomic testing
Willing to allow access to relevant medical records for research purposes
Willing to participate in study procedures, including follow-up visits for atleast 12 and 24 weeks
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
They have previously undergone genetic testing (direct-to-consumer or clinical) for a gene
relevant to the drug being studied
They are pregnant or lactating
Their life expectancy is estimated by their clinical team to be less than three months
They are inpatients with a hospital stay expected to be less than 72 hours, as this time frame is insufficient for acting upon PGx results
They are unable to provide informed consent for the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 29411 0
Toowoomba Hospital - Toowoomba
Recruitment postcode(s) [1] 45731 0
4350 - Toowoomba

Funding & Sponsors
Funding source category [1] 321636 0
Government body
Name [1] 321636 0
National Health and Medical Research Council
Country [1] 321636 0
Australia
Primary sponsor type
University
Name
Griffith University
Address
Country
Australia
Secondary sponsor category [1] 324559 0
None
Name [1] 324559 0
None
Address [1] 324559 0
Country [1] 324559 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320158 0
Darling Downs Hospital and Health Service Human Research Ethics Committee
Ethics committee address [1] 320158 0
Ethics committee country [1] 320158 0
Australia
Date submitted for ethics approval [1] 320158 0
03/11/2025
Approval date [1] 320158 0
26/11/2025
Ethics approval number [1] 320158 0
HREC/2025/QTDD/118469
Ethics committee name [2] 320191 0
Griffith University Human Research Ethics Committee
Ethics committee address [2] 320191 0
Ethics committee country [2] 320191 0
Australia
Date submitted for ethics approval [2] 320191 0
14/11/2025
Approval date [2] 320191 0
19/12/2025
Ethics approval number [2] 320191 0
2025/887

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149638 0
Prof Shivashankar H. Nagaraj
Address 149638 0
Building N27,Griffith University — Nathan Campus,QLD 4111
Country 149638 0
Australia
Phone 149638 0
+61 430423220
Fax 149638 0
Email 149638 0
Contact person for public queries
Name 149639 0
Shivashankar H. Nagaraj
Address 149639 0
Building N27,Griffith University — Nathan Campus,QLD 4111
Country 149639 0
Australia
Phone 149639 0
+61 430423220
Fax 149639 0
Email 149639 0
Contact person for scientific queries
Name 149640 0
Shivashankar H. Nagaraj
Address 149640 0
Building N27,Griffith University — Nathan Campus,QLD 4111
Country 149640 0
Australia
Phone 149640 0
+61 430423220
Fax 149640 0
Email 149640 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Individual participant data will not be publicly shared due to the sensitive nature of genetic information, participant privacy requirements, and Indigenous data governance principles. Data will remain securely stored and will only be accessed by authorised members of the approved research team in accordance with ethics approvals and institutional governance requirements.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.